Florida-based Contract Development and Manufacturing Organisation (CDMO) GBI Biomanufacturing announced on Monday that it has entered into a manufacturing collaboration with Texas-based Allterum Therapeutics, a Fannin-Founded Company.
This partnership is intended to advance Allterum's lead candidate 4A10 into clinic. The product, a monoclonal antibody (mAb), is aimed at CD127, a receptor expressed by a broad variety of cancers.
Under the collaboration, GBI will produce 4A10 for Phase 1/2a clinical trials. Allterum's initial trial will focus on patients with acute lymphoblastic leukaemia (ALL), with subsequent expansion to trials in patients with other CD127-expressing haematological malignancies, including lymphomas and acute myeloid leukaemia.
Allterum's 4A10 development programme is supported by grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the National Cancer Institute (NCI) and the NCI Experimental Therapeutics Program (NExT). Invented at the NCI, the antibody is licensed exclusively to Allterum. Allterum has received Orphan Drug and Rare Pediatric Disease designations for ALL from the FDA.
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
TME Pharma secures EUR2.4m grant for NOX-A12 Phase 2 trial
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Johnson & Johnson reports strong Phase 3 results for TREMFYA in Crohn's Disease
Kind Pharmaceutical's AND017 receives US FDA Orphan Drug Designation
RiboX Therapeutics' RXRG001 Phase I/IIa Study IND application receives US FDA approval
Modalis Therapeutics receives Orphan Drug Designation for MDL-101
EpiVax and CUBRC receive USD2m contract from US FDA
U.P. Oncolytics' oncolytic virus-based therapy granted US FDA Orphan Drug designation
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service